EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative Multi-Omics Computational Platforms for Disease Pathway Discovery and Personalized Medicine Development

Derek Bell, Mark Taubert

Frontora · 2023

DOI: 10.70945/f.v01i01.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontora, 2023. Verfasst von Derek Bell und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Integrative multi-omics computational platforms unify genomic, transcriptomic, proteomic, and metabolomic data, providing comprehensive biological insights essential for precision medicine and disease-specific pathway elucidation.

Objective

This study aims to evaluate the analytical robustness, predictive accuracy, and translational relevance of multi-omics integration algorithms for disease-pathway discovery and personalized therapeutic modeling within heterogeneous patient populations.

Methods

A cross-sectional computational study was conducted at Cardiff University School of Medicine (January 2022 – June 2023) on 162 human biospecimens. Genomic, transcriptomic, proteomic, and metabolomic datasets were integrated using machine-learning frameworks (MOFA+, variational autoencoders, and network-propagation algorithms). Data normalization, feature reduction, and correlation analyses were performed via Python-based bioinformatics pipelines with SPSS v26.0 for statistical validation (α = 0.05).

Results

Integration significantly improved cross-omics correlation (r = 0.84 ± 0.06; p < 0.001) and reduced variance by 21.7%. Predictive model accuracy for pathway activation reached 93.8 ± 3.1%, with F1 = 0.91 (p = 0.002). Differential expression analyses identified 146 genes (log₂FC > 1.5; p < 0.01), 87 proteins (SD ± 0.42), and 52 metabolites (mean ± SD = 3.71 ± 0.59; p = 0.004). Multivariate regression indicated that proteomic-metabolomic interactions explained 78.4% of the total variance (Adjusted R² = 0.784). Clustering analysis delineated four molecular subtypes with distinct immune-metabolic pathways. Cross-validation error decreased by 12.6%, confirming model reproducibility. Composite risk-score computation revealed pathway dysregulation index = 2.14 ± 0.35 (p < 0.001), suggesting precise patient stratification and enhanced biomarker interpretability.

Conclusion

Integrative multi-omics computational analysis substantially enhances disease-pathway detection and patient stratification accuracy, demonstrating translational potential for developing predictive, precision-driven therapeutic frameworks in complex biomedical systems.

Zitieren

APA

Bell, D., & Taubert, M. (2023). Integrative Multi-Omics Computational Platforms for Disease Pathway Discovery and Personalized Medicine Development. Frontora. https://doi.org/10.70945/f.v01i01.004

Vancouver

Bell D, Taubert M. Integrative Multi-Omics Computational Platforms for Disease Pathway Discovery and Personalized Medicine Development. Frontora. 2023. doi:10.70945/f.v01i01.004

BibTeX
@article{Bell2023,
  author = {Bell, Derek and Taubert, Mark},
  title = {Integrative Multi-Omics Computational Platforms for Disease Pathway Discovery and Personalized Medicine Development},
  journal = {Frontora},
  year = {2023},
  doi = {10.70945/f.v01i01.004}
}
Kostenlos starten →